Novo Nordisk to Present 35 Abstracts at the International Society on Thrombosis and Haemostasis Congress

PR69167

BAGSVAERD, Denmark, July 3 /PRNewswire=KYODO JBN/--

    Novo Nordisk announced today that data from 35 abstracts will be presented

at the upcoming International Society on Thrombosis and Haemostasis

[http://www.isth.org ] (ISTH) congress from 8-13 July, in Germany. This data

will be featured across posters, abstracts and oral presentations covering a

wide range of Novo Nordisk's haemophilia treatment options.

    The broad range of data to be presented supports Novo Nordisk's commitment

to improving lives of people with haemophilia through improved diagnosis,

treatment and care. The programme provides updates on the innovative pipeline,

as well as clinical data around established treatments. Following are key data

highlights to be presented at the meeting:

    Tuesday 11 July, 09.30 CEST, oral presentation

    - Evaluation of safety and establishment of a PK/PD relationship of

concizumab in haemophilia A patients

    Tuesday 11 July, 12.00 CEST, poster presentation

    - End-of-trial results from a large multinational extension trial

(guardian(TM)2) using turoctocog alfa for prophylaxis and treatment of bleeding

in patients with severe haemophilia A

    Wednesday 12 July, 12.00 CEST, poster presentation

    - Plasma steady state PEG concentrations are reached in patients after

once-weekly prophylactic treatment with N9-GP

    Wednesday 12 July, 14.45 CEST, oral presentation

    - Factor VIII concentration and the risk of spontaneous bleeding following

treatment with rFVIII (turoctocog alfa) in patients with severe haemophilia A

    "Novo Nordisk continues to develop a rich research and development pipeline

to ensure we are at the forefront of finding superior next generation of

medicines for people with haemophilia," said Mads Krogsgaard Thomsen, executive

vice president and chief science officer, Novo Nordisk. "The ISTH congress

gives us a great opportunity to share updates on our latest approach to

improving outcomes as well as learn more about how we can help people with

haemophilia live a life with as few limitations as possible."

    In addition to the data presentation, ISTH will also feature the launch of

CogulationASSAYS.com [http://cogulationassays.com ], a new online portal to

help address the unmet need in the diagnosis and monitoring of selected

bleeding disorders by providing information about commonly used diagnostic and

monitoring laboratory tests. The portal will officially launch on 9 July,

targeting healthcare professionals with an interest in coagulation assays,

including laboratory managers, specialists and clinicians. The site will

include a comprehensive list of coagulation assay kits and reagents currently

marketed and available for diagnostic use specific to the relevant bleeding

disorders.

    The abstracts above are a sampling of the data that will be presented by

Novo Nordisk. For a complete list of abstracts please visit:

http://www.isth2017.org/abstract-submission.html. To find out more about Novo

Nordisk at ISTH, please visit: http://www.novonordiskisth2017.com.

    About Novo Nordisk  

    Novo Nordisk is a global healthcare company with more than 90 years of

innovation and leadership in diabetes care. This heritage has given us

experience and capabilities that also enable us to help people defeat other

serious chronic conditions: haemophilia, growth disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in

77 countries and markets its products in more than 165 countries. For more

information, visit novonordisk.com [http://www.novonordisk.com ], Facebook

[http://www.facebook.com/novonordisk ],

Twitter[http://www.twitter.com/novonordisk ],

LinkedIn [http://www.linkedin.com/company/novo-nordisk ], YouTube

[http://www.Youtube.com/novonordisk ]  

    Further information

    Media:

    Katrine Sperling

    +45-3079-6718

    krsp@novonordisk.com

    Asa Josefsson

    +45-3079-7708

    aajf@novonordisk.com

    Investors:

    Peter Hugreffe Ankersen

    +45-3075-9085

    phak@novonordisk.com

    Hanna Ögren

    +45-3079-8519

    haoe@novonordisk.com

    Anders Mikkelsen

    +45-3079-4461

    armk@novonordisk.com

    Kasper Veje (US)

    +1-609-235-8567

    kpvj@novonordisk.com

    SOURCE: Novo Nordisk